RxDoctor Payments Data

Laura Clutter

Family · Wilmington, OHNPI 1922692839

Payments from drug & device makers

$775in general payments, 2019–2025

Across 31 payments — averaging $25.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$264
  • AbbVie$105
  • Lilly USA, LLC$76
  • Exact Sciences$45
  • Novo Nordisk$37
  • Dexcom, Inc.$32
  • plus $216 from 10 others

What the payments were for

  • Food & beverage$775100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$775 in reported general payments places this provider in the 65th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$72,593
Medicare patients
195
Services billed
1,103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$47,249
OzempicSemaglutide36$45,127
TrulicityDulaglutide22$31,928
MounjaroTirzepatide29$30,166
JardianceEmpagliflozin29$26,205
JanuviaSitagliptin Phosphate31$22,424
XareltoRivaroxaban19$20,354
Tresiba Flextouch U-200Insulin Degludec30$19,663
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,085
Tresiba Flextouch U-100Insulin Degludec20$11,389
Breo ElliptaFluticasone/Vilanterol13$9,536
MyrbetriqMirabegron16$8,416
Aimovig AutoinjectorErenumab-Aooe11$8,143
DuleraMometasone/Formoterol16$5,546
GemtesaVibegron11$5,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$76$62,09351 claims
PfizerEliquis$28$47,24949 claims
Novo NordiskOzempic$37$45,12736 claims
MerckJanuvia, Dulera$21$27,97047 claims
GSKTrelegy Ellipta, Breo Ellipta$30$21,62128 claims
Astellas Pharma US IncMyrbetriq$25$8,41616 claims
AbbVieSynthroid$105$1,15826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,812 family providers in Ohio.

Other family in Wilmington

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →